Central neurotoxicity of immunomodulatory drugs in multiple myeloma
Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurot...
Main Authors: | Urmeel H. Patel, Muhammad A. Mir, Jeffrey K. Sivik, Divisha Raheja, Manoj K. Pandey, Giampaolo Talamo |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2015-03-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | http://www.pagepress.org/journals/index.php/hr/article/view/5704 |
Similar Items
-
Immunomodulatory Compounds (Imids®) in the Treatment of Multiple Myeloma
by: Gordan Srkalovic, et al.
Published: (2009-10-01) -
Next-generation immunomodulatory drugs in multiple myeloma
by: Anna Suska, et al.
Published: (2019-12-01) -
Thalidomide and its analogues in the treatment of Multiple Myeloma
by: Latif Tahir, et al.
Published: (2012-09-01) -
Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
by: Antonio Piccolomo, et al.
Published: (2020-09-01) -
Immunomodulatory drugs (IMiDs) in multiple myeloma: mechanism of action and clinical implications
by: Xu, Mengni
Published: (2017)